Skip to main content

Table 1 Demographics, indications and outcomes

From: Prospective monitoring improves outcomes of primary total hip replacement: a cohort study

 

Monitoring (n = 62)

Control (n = 283)

p-value

Age †

68 (45–90)

62 (23–86)

0.68

Gender *

   

   Female

45 (73)

206 (73)

0.94

   Male

17 (27)

77 (27)

 

Indication *

   

   OA

52 (84)

220 (78)

0.56

   RA

4 (6)

34 (12)

 

   AVN

4 (6)

16 (6)

 

   DDH

2 (3)

13 (5)

 

Adverse Event *

   

   Any AE

13 (21)

127 (45)

<0.001

   Hip dislocation

0 (0)

17 (6)

0.05

   Oliguria

3 (5)

54 (19)

0.007

   SSI

0 (0)

8 (3)

0.37

   VTE

0 (0)

8 (3)

0.37

   ADR

8 (13)

31 (11)

0.66

VTEPP adherence *

61 (98)

241 (85)

0.002

  1. Abbreviations: OA: osteoarthritis; RA: rheumatoid arhtritis; AVN: avascular necrosis of the femoral head; DDH: developmental displasia of the hip; AE: adverse event; SSI: surgical site infection; VTE: venous thromboembolic event; ADR: adverse drug reaction; VTEPP: venous thromboembolic event prophylaxis protocol; † values as means in years, ranges in parentheses; * values as number of patients, percentages in parentheses.
Back to article page

Patient Safety in Surgery

ISSN: 1754-9493